Janssen Research & Development, Llc

This study compares two medications, guselkumab and risankizumab, to see which is more effective at controlling moderate to severe Crohn's disease. About 530 adults with active Crohn's will receive one of the two drugs. The main goal is to see how many achieve deep remission—mean…

This early-phase study tests an experimental drug called JNJ-87890387 in people with advanced solid tumors (kidney, ovarian, uterine, colorectal, or lung cancer) that have spread or cannot be removed. The main goals are to find a safe dose and check for side effects. About 200 pa…

This study tests a new drug called bleximenib for people with acute leukemia that has come back or not responded to other treatments. The drug targets specific genetic changes in the cancer cells. The study will first find the best dose and then check if it can safely help patien…

This early-stage study tests a new drug combination for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The treatment uses a T-cell redirecting agent (pasritamig) plus an A2a receptor blocker to help the immune system attack c…

This study tests two new drug combinations (Tal-P and Tal-Tec) against standard treatments for people with multiple myeloma that has returned or stopped responding after 1 to 4 prior therapies. About 795 participants will be randomly assigned to one of the combinations or standar…

This study tests a medicine called nipocalimab in pregnant women whose babies are at high risk for severe hemolytic disease (HDFN), a condition where the mother's immune system attacks the baby's red blood cells. The goal is to see if the drug can prevent serious problems like se…

This study tests a drug called amivantamab, alone or with standard chemotherapy, in people with advanced colorectal cancer that has spread. The goal is to see if the drug can shrink tumors and to find the safest dose when combined with chemo. About 225 adults whose cancer has not…

This study tests a new drug, JNJ-79635322, against another antibody treatment for people with multiple myeloma that has returned or stopped responding after at least three prior therapies. About 400 participants will be randomly assigned to one of the two treatments. The goal is …

This study tests a new drug called JNJ-88545223 in 240 adults with active psoriatic arthritis, a condition causing joint pain and skin patches. Participants will receive either the drug or a placebo to see if it improves joint swelling and skin symptoms. The goal is to find a bet…

This study compares two drug combinations as first treatment for people with a specific type of advanced colorectal cancer that cannot be removed by surgery or has spread. About 1000 adults will receive either amivantamab plus chemotherapy or cetuximab plus chemotherapy. The goal…

This study tests a new drug (JNJ-78278343) combined with other treatments for men whose prostate cancer has spread and no longer responds to hormone therapy. The goal is to find the safest and most effective dose and to monitor side effects. About 300 participants will be enrolle…

This study tests how well nipocalimab works compared to efgartigimod for people with generalized myasthenia gravis, a condition where the immune system attacks nerve-muscle connections, causing weakness. About 115 adults will receive one of the two drugs to see which better contr…

This early-stage study tests a combination of two experimental drugs for men with a type of advanced prostate cancer that no longer responds to hormone therapy. The first drug is designed to direct the body's immune T-cells to attack cancer cells, while the second delivers a toxi…

This study tests an investigational drug called JNJ-95597528 in 180 adults with moderate to severe atopic dermatitis (eczema). Participants receive either the drug or a placebo to see if it improves skin symptoms like redness, thickness, and itching. The main goal is to measure a…

This early-stage study tests an experimental drug called JNJ-79635322, a trispecific antibody designed to attack cancer cells from multiple angles. It is for people with relapsed or refractory multiple myeloma or AL amyloidosis who have tried other treatments. The main goals are …

This early-stage study tests an experimental drug called JNJ-88549968 in people with certain blood cancers (myelofibrosis or essential thrombocythemia) that have a specific CALR gene mutation. The drug is a bispecific antibody designed to redirect the body's immune T-cells to att…

This study tests a new drug called icotrokinra (JNJ-77242113) for people with active psoriatic arthritis, a condition causing joint pain and skin patches. About 750 adults who have tried other treatments will receive either the drug or a placebo. The goal is to see if the drug re…

This early-stage study tests a new drug called JNJ-95437446 in about 380 adults with advanced solid tumors, including colorectal, lung, and head/neck cancers that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Resear…

This study tests whether adding the drug amivantamab to standard chemotherapy and immunotherapy can help people with advanced head and neck cancer live longer. About 500 adults who have not had prior treatment for their recurrent or metastatic cancer will take part. The goal is t…

This early-phase study is testing a new experimental drug called JNJ-95566692, a trispecific antibody designed to attach to three different targets on lymphoma cells and immune cells to help the body fight the cancer. The study includes about 130 adults with B-cell non-Hodgkin ly…

This study tests whether a new drug called amivantamab, combined with standard chemotherapy (FOLFIRI), helps people with a certain type of advanced colorectal cancer live longer without their disease getting worse. It is for patients whose cancer has returned or spread and who ha…

This early-phase study tests a new drug (JNJ-79635322) combined with standard treatments for multiple myeloma, a blood cancer. About 140 participants will receive different drug combinations to find the safest and most effective dose. The goal is to control the disease, not cure …

This study tests a combination of two drugs, amivantamab and olomorasib, in people with a specific type of advanced lung cancer (KRAS G12C mutation) that has spread. The goal is to find the best dose and see if the combo can shrink tumors or slow their growth. About 60 participan…

This study tests a new drug called pasritamig, which helps the body's immune cells attack prostate cancer cells. It is for people with advanced prostate cancer that has spread and no longer responds to hormone therapy. About 663 participants will receive either pasritamig plus be…

This study tests a new drug called talquetamab for people with multiple myeloma, a type of blood cancer, that has returned or not responded to other treatments. The drug is designed to help the immune system attack cancer cells. About 510 participants will receive the drug to see…

This study is testing how well the drug guselkumab works for people with psoriatic arthritis (PsA), a condition that causes joint pain and swelling. Researchers will use ultrasound to measure joint inflammation in 200 adults over 24 weeks. The goal is to see if guselkumab reduces…

This study tests a drug called amivantamab, alone or with other cancer medicines, in people with head and neck cancer that has spread or come back. The goal is to see if these treatments can shrink tumors and are safe. About 287 adults will take part.

This study follows 150 people with early-stage bladder cancer (NMIBC) who are receiving TAR-200 treatment in everyday medical practice. Researchers want to see how long it takes for the cancer to come back or get worse after starting TAR-200. The goal is to understand how well th…

This study tests whether a nasal spray containing esketamine, given alongside standard care, can quickly reduce symptoms of major depression and suicidal thoughts in teenagers. About 258 adolescents with acute suicidal thoughts will receive either the active spray or a placebo th…

This study tracks 380 people with a common type of advanced lung cancer (EGFR-mutated NSCLC) who are already receiving the approved drug amivantamab as part of their normal care. Researchers will collect information on how long patients stay on treatment and how well it controls …

This study aims to understand sleep patterns in people with major depressive disorder who have either moderate-to-severe insomnia or mild-to-no insomnia. About 80 participants will wear a headband at home that records brain activity during sleep, and also fill out sleep diaries a…

This study looks at how the body absorbs, breaks down, and gets rid of a radioactive form of the drug bleximenib in 10 people with acute leukemia. Participants have a type of leukemia that has come back or not responded to other treatments. The goal is to understand the drug's pa…